Home / Ingredients / Berberine
Supportive but heterogeneous evidence for glycemic and lipid outcomes in type 2 diabetes; weight-loss evidence is inconclusive.
NCCIH reports some evidence that berberine may improve blood glucose, insulin resistance, and lipid measures in people with type 2 diabetes, but study quality, populations, formulations, and effects vary. Evidence for weight loss is not conclusive.
Published studies use varied formulations and doses, often in people with diabetes or other metabolic disease. Results should not be generalized to all users or all products.
Common adverse effects are gastrointestinal. Berberine can interact with medicines and should not be used during pregnancy or breastfeeding or given to infants.
S-BALANCE and NOURISH+ list berberine, but current manufacturer pages do not establish a trial-equivalent berberine dose. Product-level glucose or weight-loss claims therefore remain unverified.
Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis (Systematic review and meta-analysis of randomized controlled trials; PMID 36467075)
Population/scope: 37 studies; 3,048 people with type 2 diabetes
Evidence scope: Fasting glucose, HbA1c, 2-hour postprandial glucose, and adverse events
Finding: Pooled analyses found reductions in fasting glucose, HbA1c, and 2-hour postprandial glucose; hypoglycemia risk was not significantly increased.
Limitations: Trials varied in baseline glycemia, dose, formulation, and co-therapy. Findings apply to people with type 2 diabetes and do not establish weight-loss efficacy or finished-product effects.
Directness: Relevant human evidence · verified 2026-10-02
Important: Ingredient-level evidence is not proof that a finished product has the same effect. Dose, form, population, duration, and formulation must match.
For informational purposes only; not individualized medical advice.